All In Biotech

Drug Trial Radar · NCT05153135

Description of Treatment Patterns and Description and Comparison of Healthcare Resource Utilization and Costs of Women With Metastatic HR+/HER2- Breast Cancer Treated With CDK4/6 Inhibitors

Last checked: Nov 19, 2026Latest source record: Dec 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

4,320

Actual

Start

May 8, 2020

Primary completion

Jul 31, 2020

Study completion Jul 31, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 10, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study was an observational, retrospective cohort design, using US administrative insurance claims data, to better understand Healthcare resource utilization (HRU) and healthcare costs among women with mBC initiated on a CDK4/6 inhibitor.

Conditions

  • Metastatic Breast Cancer

Interventions

  • RibociclibDrug

    Participants who initiated CDK4/6i therapy

  • PalbociclibDrug

    Participants who initiated CDK4/6i therapy

  • AbemaciclibDrug

    Participants who initiated CDK4/6i therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of inpatient (IP) admissionsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  2. Number of IP daysTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  3. Number of days with durable medical equipment (DME) servicesTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  4. Number of days with emergency department (ED) visitsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  5. Number of days with outpatient (OP) services or visitsTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  6. Other medical servicesTime frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)
  7. Total healthcare costs (medical service + pharmacy costs)Time frame: From the index date defined as initiation of CDK4/6 inhibitor to the end of follow-up i.e. approximately 6 months (Q1/2001 - Q3/2018)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    East Hanover, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.